TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Research from R.K. Srivastava and co-authors provides new data about tuberculosis
May 26th, 2009
"Isoniazid, rifampicin and pyrazinamide during short-course chemotherapy for tuberculosis can result in liver injury. The coexistence of tuberculosis and diabetes is common in patients who receive inadequate treatment, The risk of hepatotoxicity from many toxicants is increased at diabetic rats," scientists writing in the journal Methods and Findings in Experimental and Clinical Pharmacology report. "Silymarin provides protection against liver injury caused by many hepatotoxicants, including antitubercular drugs (ATDs). In the wake of increased severity of ATD-induced hepatotoxicity in diabetes we report here the results of a study on the influence of diabetes on...
Source: TB & Outbreaks Week (2009-05-26)
|
